Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secondary Hypogonadism

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38153   clinical trials with a EudraCT protocol, of which   6266   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Secondary Hypogonadism. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005640-25 Sponsor Protocol Number: Tostran2v1 Start Date*: 2008-05-08
    Sponsor Name:Greater Glasgow & Clyde Health Board
    Full Title: Effect of Tostran 2% Gel on Growth, Development & Bone Turnover in Hypogonadal Adolescent Boys
    Medical condition: Delayed puberty or hypogonadism in boys requiring pubertal induction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021011 Hypogonadism male LLT
    9.1 10043335 Testicular hypogonadism LLT
    9.1 10052649 Primary hypogonadism LLT
    9.1 10059594 Secondary hypogonadism LLT
    9.1 10059597 Central hypogonadism LLT
    9.1 10014692 Endocrine abnormalities of puberty HLT
    9.1 10012205 Delayed puberty LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001012-11 Sponsor Protocol Number: NAT-2017-01 Start Date*: 2017-08-01
    Sponsor Name:Acerus Biopharma Inc.
    Full Title: A multicenter, open label, variable dose, two arm pilot paediatric phase 1 PK study to evaluate testosterone nasal gel (4.5% w/w) in hypogonadal boys
    Medical condition: Primary and secondary hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10052649 Primary hypogonadism PT
    20.0 10014698 - Endocrine disorders 10059594 Secondary hypogonadism PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002304-33 Sponsor Protocol Number: no sponsor Start Date*: 2006-09-12
    Sponsor Name:Rijnstate Hospital
    Full Title: Letrozole Treatment to Normalize Serum Testosterone in Men with Hypogonadotropic Hypogonadism due to Pituitary Damage.
    Medical condition: Hypogonadotropic hypogonadism in men with pituitary damage other than irradiation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001258-25 Sponsor Protocol Number: MK8962-031-00 Start Date*: 2012-11-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing...
    Medical condition: Hypogonadotropic hypogonadism (HH) in males may result from either absent or inadequate gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus or failure of pituitary gonadotropin secr...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002155-25 Sponsor Protocol Number: TAK-448-2001 Start Date*: 2014-11-17
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism
    Medical condition: Hypogonadotropic Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004866-16 Sponsor Protocol Number: I5E-MC-TSAT Start Date*: 2013-06-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men.
    Medical condition: Male hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10021011 Hypogonadism male PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004729-42 Sponsor Protocol Number: 22102014 Start Date*: 2015-04-13
    Sponsor Name:Odense University Hospital, department M [...]
    1. Odense University Hospital, department M
    2. Odense University Hospital
    Full Title: The effect of testosterone replacement in patients with hypogonadotroph hypogonadism due to opioid treatment for non-malignant disease A double-blinded, randomized and placebo-controlled trial
    Medical condition: Male Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004891-36 Sponsor Protocol Number: L00074TD301 Start Date*: 2005-04-01
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: CROSS-OVER COMPARISON OF TESTOSTERONE SERUM LEVELS IN HYPOGONADAL MEN TREATED WITH L0074 TESTOSTERONE PATCH 60CM2 (2 patches/48H) AND ORAL TESTOSTERONE UNDECANOATE -PANTESTONE® 40mg- (2 caps, bid)
    Medical condition: Men aged > 18 years old with primary or secondary hypogonadism. Only patients meeting the inclusion criteria will be enrolled in this study.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10021011 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-021268-13 Sponsor Protocol Number: Letrozole2010-1 Start Date*: 2010-11-19
    Sponsor Name:University College Dublin
    Full Title: The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial
    Medical condition: Obesity Related Male Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029883 Obesity LLT
    12.1 10021011 Hypogonadism male LLT
    Population Age: Adults Gender: Male
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005760-42 Sponsor Protocol Number: MBGS205 Start Date*: 2016-05-25
    Sponsor Name:Mereo BioPharma 2 Limited
    Full Title: A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism
    Medical condition: Hypogonadotropic hypogonadism (HH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002365-19 Sponsor Protocol Number: - Start Date*: 2018-08-22
    Sponsor Name:Line Velling Magnussen
    Full Title: Muscle strength and -mass after bariatric surgery - a possible effect of testosterone replacement therapy? Randomized, placebo-controlled and double-blinded study
    Medical condition: General aim To investigate the effect and clinical relevance of testosterone therapy combined with exercise and diet counselling in hypogonadal men undergoing bariatric surgery. Objectives To eval...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10021011 Hypogonadism male PT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001878-18 Sponsor Protocol Number: MK8962-043 Start Date*: 2017-07-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (corifollitropin alfa) in Combination with human Chorionic Gonadotropin (hCG) for Initiat...
    Medical condition: Treatment of adolescent males 14 to <18 years old with HH
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Ongoing) DK (Prematurely Ended) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-002607-17 Sponsor Protocol Number: TSX/01/C Start Date*: 2005-11-18
    Sponsor Name:Prostrakan Pharmaceuticals Ltd
    Full Title: Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus
    Medical condition: Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Ongoing) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000870-51 Sponsor Protocol Number: CMCS240281 Start Date*: 2013-02-25
    Sponsor Name:Unidad de Gestión Clínica de Endocrinología y Nutrición
    Full Title: RANDOMIZED CLINICAL TRIAL TO ASSESS THE EFFICACY OF TESTOSTERONE UNDECANOATE, METFORMIN, OR THE COMBINATION OF BOTH, FOR THE TREATMENT OF ISOLATED HYPOGONADOTROPIC HYPOGONADISM AND ERECTILE DYSFUNC...
    Medical condition: Isolated hypogonadotropic hypogonadism related to obesity
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006305-25 Sponsor Protocol Number: 2007-006305-25 Start Date*: 2008-02-15
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome
    Medical condition: Obese adults with Prader Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036476 Prader-Willi syndrome LLT
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000469-39 Sponsor Protocol Number: B9R-HL-GDGN Start Date*: 2007-05-02
    Sponsor Name:Oy Eli Lilly Finland Ab
    Full Title: An Open Label Follow-up Study of Patients Who Participated in Clinical Study B9R-HL-GDDV. A Phase IV, one-arm follow-up study to assess final adult results of GH treatment in patients with the Pra...
    Medical condition: Prader-Willi syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036476 Prader-Willi syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2015-000660-33 Sponsor Protocol Number: ZAF-312 Start Date*: 2015-09-30
    Sponsor Name:Zafgen Inc.
    Full Title: Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of Beloranib in Obese Subjects with Prader-Willi Syndrome to Evaluate Food-related Behavior, Total Body Weight, and Safety Over 52 Weeks
    Medical condition: Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000931-16 Sponsor Protocol Number: 1054 Start Date*: 2008-08-05
    Sponsor Name:Dr G I Hackett
    Full Title: 1054 -FINAL VERSION 30th Dec 2007 Clinical and biochemical improvement in Type 2 diabetic parameters in type 2 diabetic men with symptomatic testosterone deficiency syndrome (TDS). A double blind...
    Medical condition: Male Type 2 diabetics with symptomatic testosterone deficiency and confirmed low levels of serum testosterone
    Disease:
    Population Age: Gender:
    Trial protocol: GB (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001090-23 Sponsor Protocol Number: STH14394 Start Date*: 2006-06-13
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Testosterone therapy as an adjunct to exercise rehabilitation: effects on exercise capacity, inflammatory markers and quality of life in hypogonadal males with chronic heart failure.
    Medical condition: Congestive heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003694-18 Sponsor Protocol Number: TM002 Start Date*: 2017-01-18
    Sponsor Name:Saniona A/S
    Full Title: A double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS) "Se...
    Medical condition: Prader Willi syndrome (PWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA